Posted inBiotechnology
Six Experts Map the Future of Rare Metabolic Disease Research
Rare diseases are defined individually by their scarcity, but collectively they represent one of the largest burdens of unmet medical…
Posted inBiotechnology
Prenatal Mercury at Real-World Levels Rewires Development Differently in Male and Female Rats
A single pollutant, swallowed by a pregnant mother in doses that would not raise eyebrows at a seafood counter, may…
Posted inBiotechnology
Taxing Food Emissions Could Reshape Diets Across Borders, Study Finds
Fiscal policy has long been a blunt instrument in the hands of governments, but a growing body of research suggests…
Posted inBiotechnology
New Genetic Factor Analysis Method Reveals Hidden Shared Roots of Disease
A team of statisticians and geneticists has unveiled a powerful new computational method that promises to untangle one of the…
Posted inBiotechnology
Three-Day Methadone Bridge Therapy Keeps People in Opioid Treatment, Study Finds
Methadone remains one of the most effective medications available for opioid use disorder, yet in the United States it is…
Posted inBiotechnology
Fixing Salty Soils Could Halve Nitrogen Pollution and Add Billions in Crop Value
Across the planet, more than a billion hectares of farmland are quietly being poisoned by salt. As irrigation water evaporates…
Posted inBiotechnology
Stress Tests Reveal the Hidden Weaknesses of AI Credit Scoring Models
The algorithms that decide who gets a credit card, a mortgage, or a business loan are among the most consequential…
Posted inBiotechnology
New Immune Checkpoint Discovery Explains Why Gastric Cancers Ignore PD-1 Drugs
One of the most stubborn puzzles in cancer immunotherapy may have just cracked open. In a study published in Advanced…
Posted inBiotechnology
Trump’s Department of War bets $47M on Flagship biotechs to develop countermeasures
The Department of War has awarded Flagship Pioneering $47 million to develop medical countermeasure technologies against emerging threats.
Posted inBiotechnology
Enveda reaps $311M series E to feed ambition to become a ‘household name’
Enveda has raised a $311 million series E round, positioning the nature-derived drug discovery company to pursue its goal of…